Can a new vaccine shield against COVID-19? a trial aims to find out
NCT ID NCT07728396
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial tests an experimental COVID-19 vaccine called GC4006A in healthy adults aged 19 to 64. The goal is to see if the vaccine is safe and triggers an immune response. Participants receive a single shot of either the vaccine or a placebo, and researchers monitor for side effects and measure antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental COVID-19 vaccine called GC4006A
- What this could lead to
- If successful, this could lead to a new option for preventing COVID-19.
- What could go wrong
- This is an early phase 1 trial with only 72 participants, so safety and immune response are still uncertain. Side effects may occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Korea University Guro Hospital
Seoul, 08308, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?